|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Effect of diabetes mellitus on sleep quality显示文摘Diabetes mellitus(DM) is a highly prevalent condition affecting about 347 million people worldwide. In addition to its numerous clinical implications, DM also exerts a negative effect on patient's sleep quality.Impaired sleep quality disrupts the adequate glycemic control regarded as corner stone in DM management and also lead to many deleterious effects causing a profound impact on health related quality of life. This article outlines various factors leading to impaired sleep quality among diabetics and delineates how individual factor influences sleep. The article also discusses potential interventions and lifestyle changes to promote healthy sleep among diabetics. | Salim Surani Veronica Brito Asif Surani Shekhar Ghamande | 2015 | World Journal of Diabetes2015，6，6： | 3 |
| 2 | Critically ill patients and gut motility: Are we addressing it?显示文摘Gastrointestinal(GI) dysmotility is a common problemin the critically ill population. It can be a reflection and an early sign of patient deterioration or it can be an independent cause of morbidity and mortality. GI dysmotility can be divided for clinical purposes on upper GI dysmotility and lower GI dysmotility. Upper GI dysmotility manifests by nausea, feeding intolerance and vomiting; its implications include aspiration into the airway of abdominal contents and underfeeding. Several strategies to prevent and treat this condition can be tried and they include prokinetics and post-pyloric feeds. It is important to note that upper GI dysmotility should be treated only when there are clinical signs of intolerance(nausea, vomiting) and not based on measurement of gastric residual volumes. Lower GI dysmotility manifests throughout the spectrum of ileus and diarrhea. Ileus can present in the small bowel and the large bowel as well. In both scenarios the initial treatment is correction of electrolyte abnormalities, avoiding drugs that can decrease motility and patient mobilization. When this fails, in the case of small bowel ileus, lactulose and polyethylene glycol solutions can be useful. In the case of colonic pseudo obstruction, neostigmine, endoscopic decompression and cecostomy can be tried when the situation reaches the risk of rupture. Diarrhea is also a common manifestation of GI dysmotility and the most important step is to differentiate between infectious sources and non-infectious sources. | Alfredo Vazquez-Sandoval Shekhar Ghamande Salim Surani | 2017 | World Journal of Gastrointestinal Pharmacology and Therapeutics2017，8，3： | 2 |
| 3 | Weekly paclitaxel in patients with recurrent or persistent advanced ovarian cancer显示文摘 | Ghamande S Lele S Marchetti D | 2003 | Int J Gynecol Cancer2003，13，2： | 1 |
| 4 | Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fal- lopian tube,or primary peritoneal carcinoma 显示文摘 | Matulonis UA Sharma S Ghamande S | 2012 | Gynecol Oncol2012，127，1： | 1 |
| 5 | Incremental irsk of obstrue- tive sleep apneaon cardiacsurgical outcomes显示文摘 | Kaw R Golish J Ghamande S | 2006 | J Cardiovsae Surg (Torino)2006，47，6： | 1 |
| 6 | First-line chemotherapy with paclitaxel and platinum for advanced and recurrent cancer of the cervix--a phase II study显示文摘 | Piver MS Ghamande SA Eltabbakh GH | 1999 | Gynecol Oncol1999，75，3： | 1 |
| 7 | Incremental risk of obstructive sleep apnea on cardiac surgical outcomes显示文摘 | Kaw R Golish J Ghamande S | 2006 | J Cardiovasc Surg(Torino)2006，47，6： | 1 |
| 8 | Weekly paclitaxel in patients with recurrent or persistent advanced ovarian cancer显示文摘 | S Ghamande S Lele D Marchettl | 2003 | International Journal of Gynecological Cancer2003，13，： | 1 |
| 9 | Evaluation of prognostic factors and treatment modalities in ovarian cancer,patients with brain metastases显示文摘 | Anupol N Ghamande S Odunsi K | 2002 | Gynecol Oncol2002，85，3： | 1 |
| 10 | Weekly paclitaxel in patients with recurrent or persistent advanced ovarian cancer显示文摘 | Ghamande S Lele S Marchetti D | 2003 | Int J Gynecol Cancer2003，13，2： | 1 |
| 11 | PRECEDENT: a randomized phase II trial comparingEC145 and pegylated liposomal doxorubicin (PLD) incombination, versus PLD alone, in subjects with platinum-resistant ovarian cancer 显示文摘 | Naumann RW Symanowski JT Ghamande SA | 2010 | J Clin Oncol2010，28，： | 1 |
| 12 | Weekly paclitaxel in patients with recurrent or persistent advanced ovarian cancer显示文摘 | Ghamande S Lele S Marchetti D | 2003 | Int J Gynecol Cancer2003，13，2： | 1 |
| 13 | Recombinant CD40 ligand therapy has significant antitumor effects on CD40-positive ovarian tumor xenografts grown in SCID mice and demonstrates an augmented effect with clsplatin 显示文摘 | Sharad Ghamande Bonnie L Hylander Ezogelin Oflazoglu | 2001 | Cancer Research2001，61，： | 1 |
| 14 | First-line chemotherapy with paclitaxel and platinum for advanced and recurrent cancer of the cervix-A phase Ⅱ study 显示文摘 | Piver MS Ghamande SA Eltabbakh GH | 1999 | Gynecol Oncol1999，75，： | 1 |
| 15 | Serum protein profile at re-mission can accurately assess therapeutic outcomes and survival forserous ovarian cancer显示文摘 | Wang J Sharma A Ghamande SA | 2013 | PLoS One2013，8，78： | 1 |
| 16 | High levels of CA125 in a case of a parasitic leiomyoma presenting as an abdominal mass显示文摘 | Ghamande SA Eleouu B Hamid AM | 1996 | Gynecol-Oncol1996，61，2： | 1 |
| 17 | Weekly paclitaxel in patients with recurrent or persistent advanced ovarian cancer显示文摘 | S Ghamande S Lele D Marchettl | 2003 | Intemational Joumal of Gynecological Cancer2003，13，： | 1 |
| 18 | The impatn of pre-therapy extraperitioneal surgical staging on the evaluation and treatment of patients with locally advanced cervical cancer显示文摘 | Odunsi KO Lele S Ghamand S | 2001 | Eur J Gynecol Oncol2001，22，： | 1 |
| 19 | First-line chemotherapy with paclitaxel and platinum for advanced and recurrent cancer of the cervix-a phasoe Ⅱ study显示文摘 | Piver MS Ghamande SA Eltabbakh GH | 1999 | Gynecol Oncol1999，75，3： | 1 |
| 20 | Recombinant CD40 ligand therapy has significant antitumor effects on CD40-positive ovarian tumor xenografts grown in SCID mice and demonstrates an augmented effect with cisplatin显示文摘 | Ghamande S Hylander BL Oflazoglu E | 2001 | Cancer Res2001，61，20： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员